A single-center, single-arm clinical trial to assess the safety and efficacy of fully human anti-CD19XCD22 bispecific chimeric antigen receptor (CAR) T cells (CT120A) for the treatment of relapsed/refractory B-cell malignancies
Latest Information Update: 06 Dec 2021
At a glance
- Drugs CT 120 (Primary)
- Indications B-cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 25 Nov 2021 Results published in the an IASO Biotherapeutics Media Release
- 10 Jun 2021 New trial record
- 03 Jun 2021 Results (CAR-T treatment-naive relapsed/refractory B-ALL patients) presented in an IASO Biotherapeutics media release.